Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Collagen Solutions rises as it launches new online store

The online store will sell standard collagen products directly to end users in the research market
collagen
Collagen Solutions manufactures and supplies collagen for use in regenerative medicine and other medical research

Shares in Collagen Solutions PLC (LON:COS) edged higher on Monday morning after the medical grade collagen manufacturer launched a new business-to-consumer (B2C) web-based business in the US.

The online store will sell standard collagen products directly to end users in the research market.

The Minneapolis-headquartered group called the online offering an “important initiative” as it directly connects COS with its end users and allows it to better understand and address the purchasing needs of researchers.

The company told investors that, in the longer-term, that should help it to make sure it’s supplying the right products to the right markets, the company told investors.

“This initiative serves three purposes for Collagen Solutions,” said chief executive Jamal Rushdy.

“First, it increases our access to the estimated US$200m global market for cell culture reagents.

“Secondly, it gives us a direct link with the end users of our products so that we can understand their needs and how the market for collagen is evolving.

“Finally, it establishes Collagen Solutions as the go-to collagen supplier among investigators.”

Shares gained 5% to 5.14p on Monday morning.

View full COS profile

Collagen Solutions PLC Timeline

Related Articles

Medical test
August 10 2016
The STOP-HCV-1 clinical trial will assess two direct acting anti-viral (DAA) treatment combinations and whether the addition of another, older drug has value in short course treatment
Blood testing
February 13 2017
Identifying cancer cells early is a key part of combatting the disease, and ANGLE's Parsortix device looks to be developing into a key ally.
Knee surgery
February 02 2017
The treatment involves removing cellular material from animal and human tissue to leave a matrix which gives a framework for population by the patient’s own cells.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use